Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

2025-12-31 13:29:53 ET

The last time I wrote about Prime Medicine ( PRME ) it was with respect to a Seeking Alpha article entitled as " Prime Medicine: Pressing Forward With Lead Liver Targeting Indications ". With respect to that article, I noted that the company had decided on a shift in its strategy by moving forward with two key liver disease indication programs. In essence, there was proof-of-concept [POC] established that the company's autologous hematopoietic stem cells [HSCS] modified ex vivo with Prime Editing PM359 could be effective in correcting disease-causing gene mutations for the treatment of patients with p47phox Chronic Granulomatous Disease [CGD]. ...

Read the full article on Seeking Alpha

For further details see: